Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study
Relevance. Omalizumab is recommended for treatment of severe forms of recurrent urticaria in children since 12 years old. Though the Omalizumab efficiency and safety in children with recurrent urticaria have not been studied specifically.Objective. To estimate results of the therapy including Omaliz...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
Union of pediatricians of Russia
2019-09-01
|
| 叢編: | Педиатрическая фармакология |
| 主題: | |
| 在線閱讀: | https://www.pedpharma.ru/jour/article/view/1739 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|